Innate Pharma Book Value Per Share Growth & History (IPH)
Innate Pharma's book value per share was -€0.23 for fiscal 2025.
View full Innate Pharma company overviewInnate Pharma annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -€0.23 | -€0.34 | — |
| 2024 | 2024-12-31 | €0.11 | -€0.54 | −83.66% |
| 2023 | 2023-12-31 | €0.65 | -€0.04 | −5.24% |
| 2022 | 2022-12-31 | €0.68 | -€0.67 | −49.60% |
| 2021 | 2021-12-31 | €1.35 | -€0.62 | −31.60% |
| 2020 | 2020-12-31 | €1.97 | -€0.79 | −28.63% |
| 2019 | 2019-12-31 | €2.77 | -€0.08 | −2.69% |
| 2018 | 2018-12-31 | €2.84 | €1.01 | +55.40% |
| 2017 | 2017-12-31 | €1.83 | — | — |
Innate Pharma quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | -€0.23 | -€0.34 | — |
| Q2 2025 | 2025-06-30 | €0.06 | — | — |
| Q4 2024 | 2024-12-31 | €0.11 | -€0.54 | −83.66% |
| Q4 2023 | 2023-12-31 | €0.65 | -€0.04 | −5.24% |
| Q4 2022 | 2022-12-31 | €0.68 | -€0.67 | −49.60% |
| Q4 2021 | 2021-12-31 | €1.35 | — | — |
Innate Pharma book value per share trends
Over the last five fiscal years, Innate Pharma's book value per share decreased from €1.97 to -€0.23, a change of -€2.21. The latest reported quarter, Q4 2025, shows -€0.23.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗